TAR-210 results show 90% recurrence-free survival and 90% co

/PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of...

Related Keywords

San Antonio , Texas , United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , Vilaseca , American , Prnewswire Johnson , Sabine Brookman , Rodriguez Faba , Ania Diantonio , Indianj Urol , American Cancer Society , American Urological Association , Janssen Pharmaceuticals , Johnson , Janssen Research Development , Drug Administration , Astex Pharmaceuticals , Late Development Oncology , European Association Of Urology , Bladder Cancer Advocacy Network , European Society For Medical Oncology , Exchange Commission , None Of Janssen Research Development , Janssen Biotech Inc , Oral Presentation Session , Urological Association , Annual Meeting , Bacillus Calmette Gu , European Society , Medical Oncology , European Association , Antoni Vilaseca , Sabine Brookman May , Vice President , Johnson Innovative , Breakthrough Therapy Designation , European Medicines Agency , Soft Tissue Mineralization , Embryo Fetal Toxicity , High Risk Non , Muscle Invasive Bladder Cancer , Innovative Medicine , Janssen Research , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Urology Young Academic Urologists , Urol Assoc , Bladder Cancer Advocacy , Accessed April , Johnson Amp ,